543220: Lucknow Hospital Expansion And Dividend Plans Will Shape Steady Outlook

Analysts have trimmed their price target for Max Healthcare Institute to about ₹1,173 from roughly ₹1,201. This reflects slightly revised assumptions on fair value, revenue growth, profit margins, the discount rate and future P/E multiples.

What's in the News for Max Healthcare Institute

• Max Healthcare Institute plans a Board Meeting on May 21, 2026 to consider standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, a potential final dividend on equity shares, and the reappointment of cost auditors. Source: Company Board Meeting filing dated May 21, 2026.
• The Board of Max Healthcare Institute recommended a final dividend of ₹2 per equity share, equal to 20% of the ₹10 face value, for the financial year ended March 31, 2026. This remains subject to shareholder approval at the upcoming 25th AGM. Source: Company dividend announcement dated May 21, 2026.
• The company fixed July 3, 2026 as the record date to identify shareholders eligible to receive the proposed final dividend for FY 2025 26, if approved at the AGM. Source: Company dividend announcement dated May 21, 2026.
• Max Healthcare Institute approved Phase I construction of a new Max Super Specialty Hospital on a 5 acre land parcel at Shaheed Path in Lucknow, with planned capacity of about 712 beds to be added to the network after completion. Source: Company expansion update dated May 21, 2026.
• Phase I of the Lucknow hospital project is planned with an estimated construction and equipment cost of about ₹14,000 million, or roughly ₹19.7 million per bed excluding land cost, and is expected to be funded through a mix of debt and internal accruals. Source: Company expansion update dated May 21, 2026.
• A Board Meeting is scheduled for August 13, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Source: Company Board Meeting notice dated August 13, 2026.

Valuation Changes for Max Healthcare Institute

• Fair Value has been revised from ₹1,201.04 to ₹1,172.62, representing a small downward adjustment to the implied valuation for Max Healthcare Institute.
• Discount Rate has moved from 12.514% to 12.436%, reflecting a slight reduction in the rate used to discount future cash flows.
• Revenue Growth assumption has shifted from 28.03% to 26.31%, indicating a modestly lower growth outlook for future revenues in ₹ terms.
• Net Profit Margin assumption has been adjusted from 17.86% to 17.85%, which is effectively unchanged and implies a similar earnings profile in ₹ terms.
• Future P/E multiple has moved from 54.15x to 54.14x, which is a very small change in the valuation multiple applied to future earnings.